A 58-year-old man with advanced pancreatic cancer presents to the palliative care clinic with severe, uncontrolled pain (VAS 9/10). He has been on paracetamol 1 g QID and ibuprofen 400 mg TDS for 2 weeks without relief. On examination, he appears cachectic and in distress. His vital signs are: BP 128/82 mmHg, HR 92/min, RR 16/min, SpO₂ 96% on room air. Liver function tests show mild elevation of transaminases. Which opioid would be the most appropriate choice for initiating analgesia in this patient?

Explanation

## Opioid Selection in Cancer Pain Management ### Clinical Context This patient has severe, opioid-naive cancer pain unresponsive to WHO Step 2 analgesics (paracetamol + NSAID). He requires urgent escalation to WHO Step 3 (strong opioid). ### Why Morphine is Optimal **Key Point:** Morphine is the gold-standard first-line strong opioid for cancer pain because it has: - Rapid onset (5–10 min IV/IM; 30–60 min oral) - Predictable pharmacokinetics - Easy titration in acute settings - No dose ceiling - Extensive clinical experience and safety data - Active metabolites (M6G, M3G) that contribute to analgesia **High-Yield:** In opioid-naive patients with severe acute pain, parenteral morphine (IV/IM) allows faster titration and better pain control than oral formulations. Start low (5–10 mg), titrate every 15–30 min until pain controlled, then convert to long-acting formulation once stable dose identified. ### Comparison with Alternatives | Feature | Morphine | Codeine | Tramadol | Fentanyl Patch | |---------|----------|---------|----------|----------------| | **Onset** | 5–10 min (IV) | 30–60 min | 30–60 min | 12–24 h (patch) | | **Potency** | Standard (1×) | Weak (1/6 morphine) | Weak–moderate | 100× morphine | | **Titratability** | Excellent | Poor (weak) | Moderate | Poor (fixed dose) | | **First-line?** | Yes | No (Step 2) | No (adjunct) | No (maintenance) | | **Acute pain?** | Yes | No | Limited | No | **Clinical Pearl:** Codeine is a prodrug requiring hepatic CYP2D6 activation; ~10% of the population are poor metabolizers, making it unreliable. Tramadol has dual action (opioid + SNRI) but is weak as monotherapy for severe pain and carries seizure risk. Fentanyl patches are for chronic, stable pain in opioid-tolerant patients—not for acute pain or opioid-naive individuals (risk of overdose). ### Dosing Strategy 1. Start morphine 5–10 mg IV/IM 2. Reassess pain in 15–30 min 3. Titrate by 50% increments until pain ≤3/10 4. Once stable, convert to oral modified-release (MR) morphine 12-hourly + immediate-release (IR) for breakthrough 5. Typical conversion: total daily parenteral dose × 3 = oral daily dose **Warning:** Do NOT start transdermal fentanyl in opioid-naive patients—risk of fatal respiratory depression. Patches are reserved for opioid-tolerant patients on stable doses (≥60 mg morphine equivalent daily). ### Hepatic Impairment Consideration Mild transaminase elevation is not a contraindication to morphine, but dose should be reduced by 25–50% if significant hepatic dysfunction (cirrhosis, jaundice, coagulopathy) is present. This patient's mild elevation does not warrant dose reduction.